Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06747299

The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

Based on the PET/CT imaging data of patients with T-NK cell lymphoma, machine learning and deep learning methods are used to extract imaging features, establish a T-NK cell lymphoma prediction model, and provide more scientific and accurate prognosis prediction for the clinic.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

T-NK Cell Lymphoma Lymphoma Lymphoma, Extranodal NK-T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Neoplasms Neoplasms by Histologic Type

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine

Shanghai, Shanghai Municipality, China

About this study

This study adopts a multicenter retrospective cohort study design，we provided PET/CT of 200 patients with T-NK cell lymphoma as an external validation set for model validation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pathological histology confirmed as T-NK Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.

Exclusion criteria

  • The patient had previously received antitumor therapy;
  • The patient had a history of other tumors;
  • Incomplete clinical information or imaging data;
  • Concomitant other malignant tumors.

Treatment and study plan

Primary outcomes

  1. Evaluation the value of Artificial Intelligence-based 18F-FDG PET/CT of T-NK Cell Lymphoma

    Time frame: Within 1 week of enrollment and after 3 months treatment

    The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma

Secondary outcomes

  1. Progress free survival

    Time frame: 3 years

    Progress free survival

  2. Overall survival

    Time frame: 3 years

    Overall survival

Study contacts

Contact information is provided by the study sponsor or research team.

Guo rui Deputy director

CONTACT

[email protected]

13361860108

Sponsors and collaborators

Lead sponsor

Ruijin Hospital

Other

Collaborators

  • West China Hospital

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 24, 2024
Registry last updated
Dec 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.